Lonza Pharma&Biotech launches biological manufacturing concept

Ibex Solutions is a modular manufacturing complex capable of supporting companies looking to carry out activities across multiple technologies — mammalian, microbial, cellular or bio-conjugate — right from late discovery to manufacture

Lonza has started constructing its new complex in Visp, which offers
facilities for those looking at biological development and manufacturing

Lonza has launched Ibex Solutions — an innovative biological development and manufacturing concept, coupling flexibility in facility-build-out and exploiting Lonza's expertise and service network in Visp (CH).

Ibex biomanufacturing comprises a modular, technology-independent development and manufacturing complex capable of supporting activities across multiple technologies — mammalian, microbial, cellular or bio-conjugate — and from late discovery to manufacture. This flexibility gives customers complete freedom in facility design and implementation and the ability to respond rapidly as their needs evolve.

Responsiveness is further enhanced by the integration of the Ibex biomanufacturing complex into the Visp site with its experienced workforce and established service networks.

Construction began in June with a formal groundbreaking ceremony expected in the second half of 2017. Several hundred new jobs are expected to be created as a result.

The path to market of a modern medicine is complex and uncertain. Under the growing pressure of regulation and competition, biopharma companies must be able to solve critical development steps under tight time and budget constraints.

Ibex Solutions include highly flexible models to match and adapt to each customer’s expectations and forecasts. The availability of a modular complex means time-to-market can be reduced by 12 months or more. These advantages contribute to a significant de-risking of major strategic investment decisions.

Marc Funk, Pharma&Biotech COO at Lonza, said: “Lonza has been creating innovative manufacturing and production solutions for 120 years and we are continuing to pioneer clinical and commercial manufacturing in multiple technologies all over the world. We have been working with our partners to understand what we can offer that will really change the game for them, and that’s why we have created Ibex.”

The solution also offers the opportunity for tailored business and ownership models, providing higher transparency and flexibility.

In addition to enabling, a cost-effective build-out and fast ramp-up, it can provide assured delivery with a simplified supply chain, as well as a stable workforce, IP protection and favourable taxation environment.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Companies